William Blair analyst Tim Lugo reiterated an Outperform rating and {REMOVEPT} price target on Atea Pharmaceuticals (NASDAQ: AVIR) amid today's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Trader Talk

Atea plunges after COVID-19 treatment fails to help patients in studyOctober 19, 2021 7:48 AM Atea Pharmaceuticals Inc. (AVIR) to Resume Trading at 7:30 a.m.October 19, 2021 7:10 AM Merck (MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (AVIR) Trial Missing Primary EndpointOctober 19, 2021 7:09 AM Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary EndpointOctober 19, 2021 7:02 AM Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient SettingOctober 19, 2021 7:00 AM